Minimally Invasive Female Urinary Incontinence Devices Market by Device Type (Injectable Urethral Bulking Agents, Urethral Sling Systems, Neuromodulation Systems) and Forecast 2017-2021

Minimally Invasive Female Urinary Incontinence Devices Market by Device Type (Injectable Urethral Bulking Agents, Urethral Sling Systems, Neuromodulation Systems) and Forecast 2017-2021

Minimally invasive surgical procedures are often used to treat the most common type of incontinence, stress urinary incontinence (SUI). Injectable therapy using bulking agents is composed of synthetic materials, bovine collagen, or autologous substances. The injection of bulking agents to treat a dysfunctional urethra is a minimally invasive method of correcting intrinsic sphincteric deficiency that results in stress urinary incontinence but is being performed less frequently in current practice, due to their application has been limited by placement, durability, antigenicity, and other compatibility issues. Minimally invasive suburethral slings, namely the retropubic suburethral sling or the tension-free vaginal tape (TVT), also known as retropubic sling has become the mainstay for surgical management of moderate to severe stress urinary incontinence. The transobturator slings procedure using Transobturator tapes (TOT/TVT-O) was introduced in 2001 with the aim of decreasing the risk of complication associated with the retropubic passage of the trocar, especially bowel and bladder injury. Neuromodulation has been reported to be effective for the treatment of stress and urgency urinary incontinence. It is a well-established treatment option for patients with non-neurogenic overactive bladder and urinary retention. The cure and improvement rates of pelvic floor neuromodulation in urinary incontinence have improved over time.

The global minimally invasive female urinary incontinence devices market segmentation is based on device type (injectable urethral bulking agents, urethral sling systems, neuromodulation systems).

The global minimally invasive female urinary incontinence devices market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global minimally invasive female urinary incontinence devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global minimally invasive female urinary incontinence devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global minimally invasive female urinary incontinence devices market and profiled in this report include Axonics Modulation Technologies, Inc., Bioness, Inc., BlueWind Medical Ltd., Boston Scientific Corporation, Caldera Medical, Inc., Carbon Medical Technologies, Inc., CL Medical, Cogentix , Cogentix Medical, Coloplast Corporation, Cousin Biotech , CR Bard, Inc. , Ethicon, Inc./Johnson & Johnson, FemPulse, LLC, InterStim , Medtronic, Inc., Merz Aesthetics, Inc./Merz Pharma GmbH & Co. KGaA, NURO , Nuvectra Corporation, and StimGuard LLC.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Devices
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Device or Brand Type
    • Diagnostic Test
    • Indication Type
    • Technology
    • Diagnostics, Therapeutic or Surgical Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • Device Classification I, II, III, IV
    • Device (FDA, EMEA) Approvals
  8. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  9. Recommendations
  10. References

Minimally Invasive Female Urinary Incontinence Devices Market

1. Device Type
1.1. Injectable Urethral Bulking Agents for Stress Urinary Incontinence (SUI)
1.2. Urethral Sling Systems for Stress Urinary Incontinence
1.3. Neuromodulation Systems to Treat Overactive Bladder

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC
2.5. Rest of the World

3. Company Profiles
3.1. Axonics Modulation Technologies, Inc.
3.2. Bioness, Inc.
3.3. BlueWind Medical Ltd.
3.4. Boston Scientific Corporation
3.5. Caldera Medical, Inc.
3.6. Carbon Medical Technologies, Inc.
3.7. CL Medical
3.8. Cogentix
3.9. Cogentix Medical
3.10. Coloplast Corporation
3.11. Cousin Biotech
3.12. CR Bard, Inc.
3.13. Ethicon, Inc. (Johnson & Johnson)
3.14. FemPulse, LLC
3.15. InterStim
3.16. Medtronic, Inc.
3.17. Merz Aesthetics, Inc. (Merz Pharma GmbH & Co. KGaA)
3.18. NURO
3.19. Nuvectra Corporation
3.20. StimGuard LLC

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*